Cancer Care


A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Principal Investigator (?)
Study Number
Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy.
If the subject is sentinel node positive and meets study requirements, the subject is
randomized to receive either (1) completion lymphadenectomy (2) observation with nodal
ultrasound. Subjects are then followed for 10 years.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.